Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Plant Allergenic Extract [EPC]
Mycoplasma Pneumoniae is a non-standardized allergenic extract used primarily in diagnostic testing to assess cell-mediated immunity and in certain immunotherapy protocols.
Name
Mycoplasma Pneumoniae
Raw Name
MYCOPLASMA PNEUMONIAE
Category
Non-Standardized Plant Allergenic Extract [EPC]
Drug Count
15
Variant Count
17
Last Verified
February 17, 2026
About Mycoplasma Pneumoniae
Mycoplasma Pneumoniae is a non-standardized allergenic extract used primarily in diagnostic testing to assess cell-mediated immunity and in certain immunotherapy protocols.
Detailed information about Mycoplasma Pneumoniae
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Mycoplasma Pneumoniae.
Historically, the FDA has overseen the production of allergenic extracts to ensure they provide a consistent antigenic challenge. Because this is a 'non-standardized' extract, its potency is not measured by a federally mandated bioassay, but rather by the manufacturer's internal standards and protein concentration. Your healthcare provider may use this extract to determine if your immune system is functioning correctly or to identify specific sensitivities. It is important to distinguish the therapeutic extract from the pathogen itself; while the bacteria cause 'walking pneumonia,' the extract is a sterile preparation used for medical assessment.
At the molecular level, Mycoplasma Pneumoniae allergenic extract works by introducing specific bacterial antigens (proteins and polysaccharides) into the skin or mucosal surfaces. When these antigens are introduced, they are captured by professional antigen-presenting cells (APCs), such as dendritic cells and macrophages. These cells process the antigens and present them to sensitized T-lymphocytes. If the patient has been previously exposed to Mycoplasma pneumoniae or has a cross-reactive immune memory, these T-cells become activated and release various cytokines, including interferon-gamma and interleukin-2.
This cytokine cascade leads to the recruitment of additional inflammatory cells to the site of administration, resulting in a visible and palpable reaction known as induration (a hardened area of skin). This reaction typically peaks between 48 and 72 hours after administration. This diagnostic mechanism is a classic example of a Type IV hypersensitivity reaction. In the context of immunotherapy, repeated exposure to small, controlled amounts of the extract may help modulate the immune system's overreactivity, although this use is less common than diagnostic skin testing. The precise receptors targeted include the T-cell receptor (TCR) complex and various Toll-like receptors (TLRs) that recognize bacterial lipopeptides.
As an allergenic extract administered locally (usually intradermally), the pharmacokinetic profile of Mycoplasma Pneumoniae differs significantly from systemic drugs.
The primary FDA-recognized use for Mycoplasma Pneumoniae extract is in the assessment of cell-mediated immunity. This is often referred to as 'anergy testing.' If a patient fails to react to a battery of common antigens (including Mycoplasma, Candida, or Mumps), it may indicate a suppressed immune system, which can occur in conditions like HIV/AIDS, certain cancers, or during chemotherapy.
Additionally, it may be used in specialized allergy clinics for:
Mycoplasma Pneumoniae is typically available in the following forms:
> Important: Only your healthcare provider can determine if Mycoplasma Pneumoniae is right for your specific condition. The use of this extract must be conducted under the supervision of a clinician trained in managing potential allergic emergencies.
For diagnostic skin testing (Delayed-Type Hypersensitivity), the standard adult dose is typically 0.1 mL of the extract. This is administered intradermally, usually on the volar surface (inner side) of the forearm. The healthcare provider will use a tuberculin syringe to create a small 'wheal' or bubble under the skin.
In the context of immunotherapy, the dosage is highly individualized. It usually begins with a very low dose of a highly diluted extract (e.g., 0.05 mL of a 1:100,000 dilution) and is gradually increased over several weeks or months (the 'build-up phase') until a maintenance dose is reached. This maintenance dose is determined by the patient's tolerance and the clinical response observed by the allergist.
Mycoplasma Pneumoniae extract can be used in children, but the dosage must be carefully managed by a pediatric allergist. For diagnostic testing, the dose is generally the same as the adult dose (0.1 mL intradermally), as the goal is to trigger a localized cellular response regardless of body weight. However, children may have more sensitive skin, and the interpretation of the results must account for age-related immune system development. It is generally not recommended for infants under the age of one unless specifically directed by a specialist.
No specific dosage adjustments are typically required for patients with renal impairment, as the extract is administered locally and systemic absorption is minimal. However, patients with end-stage renal disease may exhibit 'anergy' (a lack of immune response), which can lead to false-negative results in diagnostic testing.
There are no established guidelines for dosage adjustment in hepatic impairment. Since the metabolism of the extract involves local proteolysis rather than hepatic enzyme pathways, the standard dose is generally used.
Older adults may have a diminished T-cell response due to immunosenescence (the natural aging of the immune system). While the dose remains 0.1 mL, healthcare providers must be cautious when interpreting results, as a negative test may not necessarily indicate a lack of previous exposure but rather a slower immune response.
This medication is never self-administered. It must be given by a healthcare professional in a clinical setting.
If you miss an appointment for a diagnostic skin test, it can be rescheduled at any time. However, if you are undergoing immunotherapy and miss a scheduled 'build-up' dose, your doctor may need to reduce the dose for your next injection to ensure safety and prevent a systemic reaction. Do not attempt to 'double up' on doses.
An overdose of an allergenic extract usually occurs if the concentration is too high or if the injection is accidentally given into a vein (intravenously) rather than into the skin.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Always inform your provider of any previous reactions to skin tests.
Most patients receiving Mycoplasma Pneumoniae extract for diagnostic purposes will experience some level of local reaction, as this is often the intended goal of the test. Common side effects include:
Some patients may experience more pronounced local or mild systemic reactions, such as:
Rarely, the extract can cause more significant issues:
> Warning: Stop taking Mycoplasma Pneumoniae and call your doctor immediately if you experience any of these symptoms of a systemic allergic reaction (anaphylaxis).
Because Mycoplasma Pneumoniae extract is typically used for short-term diagnostic purposes, long-term side effects are extremely rare. However, in the context of long-term immunotherapy, patients may develop:
While Mycoplasma Pneumoniae extract itself may not always carry a specific black box warning in all jurisdictions, the class of Allergenic Extracts generally carries a significant warning regarding Anaphylaxis.
Summary of Warning: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylactic shock and death. These agents should only be administered by healthcare providers who are equipped to treat such reactions. Patients with unstable asthma or those taking beta-blockers may be at an increased risk of severe outcomes if a reaction occurs.
Report any unusual symptoms to your healthcare provider. Even a mild systemic symptom, like itchy palms or a scratchy throat, should be reported immediately during the observation period.
Mycoplasma Pneumoniae extract is a potent biological substance. It should only be used for the specific diagnostic or therapeutic purposes for which it was intended. It is not a vaccine and does not provide protection against 'walking pneumonia.' Patients should be aware that the accuracy of the skin test depends on a healthy immune system; therefore, recent illnesses or medications can interfere with the results.
No specific FDA black box warning exists specifically for the 'Mycoplasma Pneumoniae' extract alone; however, it falls under the general FDA mandate for Allergenic Extracts. The warning states that these products can cause severe systemic allergic reactions. Administration must take place in a facility where emergency resuscitative equipment and medications (like epinephrine) are immediately available. Patients must be observed for at least 30 minutes following administration.
Following the administration of Mycoplasma Pneumoniae extract, the following monitoring is required:
Mycoplasma Pneumoniae extract generally does not affect your ability to drive or operate machinery. However, if you experience a vasovagal reaction (fainting) or a systemic allergic reaction, you should not drive until you have fully recovered and been cleared by a medical professional.
There is no direct interaction between alcohol and Mycoplasma Pneumoniae extract. However, alcohol can cause vasodilation (widening of blood vessels), which might theoretically increase the rate of absorption of the extract or worsen a local inflammatory reaction. It is best to avoid heavy alcohol consumption on the day of the test.
For diagnostic testing, 'discontinuation' is not applicable as it is a single-use procedure. For immunotherapy, if the treatment is discontinued, the patient will gradually lose the immunological tolerance built up during the therapy. There is no 'withdrawal syndrome' associated with stopping allergenic extracts.
> Important: Discuss all your medical conditions with your healthcare provider before starting Mycoplasma Pneumoniae. Ensure they are aware of any recent viral illnesses or changes in your medication regimen.
While there are few absolute contraindications for a diagnostic skin test, Mycoplasma Pneumoniae extract should not be used in combination with:
There are no known direct food interactions with Mycoplasma Pneumoniae extract. However, patients should avoid consuming foods they are known to be highly allergic to on the day of the test, as this could prime the immune system and increase the risk of a systemic reaction to the extract.
Mycoplasma Pneumoniae extract does not typically interfere with standard blood chemistry or hematology tests. However, its use is intended to be a lab test of sorts (an in vivo diagnostic). It may interfere with other skin tests (like the TB Mantoux test) if performed at the same time and in the same location due to 'bystander' inflammatory effects.
For each major interaction, the management strategy usually involves either holding the interfering medication (under medical supervision) or delaying the skin test until the medication has cleared the system.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Do not stop taking prescribed medications like steroids or beta-blockers without first consulting the physician who prescribed them.
Mycoplasma Pneumoniae extract must NEVER be used in the following circumstances:
In these cases, a healthcare provider will perform a careful risk-benefit analysis:
Patients who are allergic to other species of Mycoplasma or related bacterial extracts may exhibit cross-reactivity. Additionally, individuals with a known sensitivity to phenol or glycerin (common stabilizers in extracts) should be tested with extreme caution or avoid the product entirely.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Mycoplasma Pneumoniae. Always provide a full list of your allergies and previous skin test results.
Mycoplasma Pneumoniae extract is generally classified in FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm when administered to a pregnant woman. Because the extract is used for diagnostic purposes, most clinicians recommend postponing the test until after the first trimester or until after delivery, unless the diagnosis of anergy is essential for the mother's immediate care. There is no evidence of teratogenicity (causing birth defects), but the risk of a systemic reaction (anaphylaxis) in the mother could lead to fetal hypoxia (lack of oxygen).
It is not known whether the antigens from Mycoplasma Pneumoniae extract are excreted in human milk. However, because the amount of protein injected is very small and the administration is local, it is highly unlikely that significant amounts would reach the nursing infant. The primary concern during breastfeeding is the mother's potential for a systemic reaction. Healthcare providers generally consider it safe to perform skin testing in breastfeeding women, provided they are monitored appropriately.
As discussed in the dosage section, Mycoplasma Pneumoniae extract is safe for use in children when administered by a specialist. However, the immune system of a child is still developing. Children under the age of 5 may show smaller reactions than adults, even if they have been exposed to the organism. It is not approved for use in neonates (newborns), as their cell-mediated immune response is not yet mature enough to provide a reliable result.
In patients over the age of 65, the prevalence of 'anergy' (no reaction to skin tests) increases significantly. This is part of the natural aging process of the thymus and T-cells. While the extract is safe for use in the elderly, a negative result must be interpreted with caution. Additionally, elderly patients are more likely to be taking medications like beta-blockers or have underlying cardiovascular disease, which increases the risk associated with a potential systemic allergic reaction.
Patients with chronic kidney disease (CKD), particularly those on dialysis, often have impaired cellular immunity. While no dose adjustment of the 0.1 mL extract is needed, the clinician must be aware that CKD patients are frequently 'anergic.' Dialysis does not clear the antigens from the skin site, as they are processed locally by the immune system.
There are no specific considerations for hepatic impairment, as the liver does not play a major role in the processing of intradermal allergenic extracts. Standard safety protocols apply.
> Important: Special populations require individualized medical assessment. Your doctor will consider your age, pregnancy status, and organ function before proceeding with the administration of this extract.
Mycoplasma Pneumoniae extract functions as an antigenic challenge to the cellular immune system. The extract contains various immunogenic components of the M. pneumoniae bacterium, including membrane lipoproteins and the P1 adhesion protein. Upon intradermal injection, these antigens are recognized by the immune system. In a sensitized individual, memory T-cells (specifically CD4+ Th1 cells) recognize the antigen presented by MHC Class II molecules on local macrophages. This recognition triggers the release of pro-inflammatory cytokines such as Interferon-gamma (IFN-γ) and Tumor Necrosis Factor-alpha (TNF-α). These cytokines increase vascular permeability and recruit more mononuclear cells to the site, creating the characteristic 'induration' or hardening of the skin that signifies a positive cell-mediated response.
The dose-response relationship for Mycoplasma Pneumoniae extract is non-linear. A very small dose (0.1 mL) is usually sufficient to trigger a maximal response in a healthy, sensitized individual. Increasing the dose does not necessarily increase the diagnostic accuracy but significantly increases the risk of skin necrosis or systemic reactions. The time to onset for the visible reaction is 24 hours, with the peak effect (maximal induration) occurring between 48 and 72 hours. Tolerance does not typically develop from a single diagnostic dose, but repeated frequent injections (as in immunotherapy) can lead to 'desensitization,' where the T-cell response is gradually dampened.
| Parameter | Value |
|---|---|
| Bioavailability | Negligible (Local Administration) |
| Protein Binding | Local Tissue Binding |
| Half-life (Local) | 24-48 Hours |
| Tmax (Reaction) | 48-72 Hours |
| Metabolism | Local Proteolysis |
| Excretion | Lymphatic/Renal (as fragments) |
The extract is a complex biological mixture and does not have a single molecular formula. It is primarily composed of water-soluble proteins, glycoproteins, and polysaccharides extracted from Mycoplasma pneumoniae cultures. The solution is usually standardized to a specific protein nitrogen unit (PNU) or weight/volume (w/v) ratio. It is soluble in the buffered saline solution used for the injection. The preparation is sterile and typically contains 0.4% phenol as a preservative to prevent bacterial overgrowth.
Mycoplasma Pneumoniae is classified as a Non-Standardized Plant Allergenic Extract [EPC], though this is a broad regulatory category that includes bacterial extracts used for similar purposes. It is related to other diagnostic antigens like Tuberculin (PPD), Candida albicans extract, and Mumps skin test antigen. Within the therapeutic area, it is considered an 'In Vivo Diagnostic Radiopharmaceutical/Biological.'
Medications containing this ingredient
Common questions about Mycoplasma Pneumoniae
Mycoplasma Pneumoniae extract is primarily used as a diagnostic tool to check if a person's cell-mediated immune system is working correctly. This is often called an 'anergy test' and is performed by injecting a small amount of the extract into the skin to see if a physical reaction occurs. If the skin becomes hard and swollen at the site, it indicates that the T-cells in the immune system are active and able to respond to a challenge. It is frequently used in patients with chronic illnesses or those suspected of having a weakened immune system. It is not used to treat pneumonia, but rather to test the body's defenses.
The most common side effects are local reactions at the site of the injection, which are actually expected during a diagnostic test. These include redness, itching, and a hardened lump called an induration. Some patients may also feel slight tenderness or soreness in the arm for a few days. These symptoms are usually mild and go away on their own without treatment. In rare cases, a person might experience a small blister or a larger area of swelling. If these local symptoms are accompanied by a rash elsewhere or difficulty breathing, it could indicate a more serious reaction.
There are no known direct interactions between alcohol and the Mycoplasma Pneumoniae extract used in skin testing. However, it is generally advised to avoid alcohol on the day of the test because alcohol can dilate your blood vessels and potentially affect how your skin reacts to the injection. Excessive drinking can also mask symptoms of a systemic allergic reaction, making it harder for you or your doctor to notice if something is wrong. For the most accurate diagnostic results, it is best to remain hydrated with water and avoid alcohol for 24 hours. Always follow the specific advice given by your healthcare provider.
Mycoplasma Pneumoniae extract is generally avoided during pregnancy unless a doctor decides the diagnostic information is absolutely necessary. While there is no evidence that the extract causes birth defects, any skin test carries a small risk of a severe allergic reaction called anaphylaxis. If a pregnant woman has a severe allergic reaction, it could potentially reduce the oxygen supply to the baby. For this reason, most doctors prefer to wait until after the baby is born to perform these types of immune system tests. If you are pregnant or planning to become pregnant, be sure to inform your doctor before the test.
The 'work' of Mycoplasma Pneumoniae extract is to trigger an immune response that can be measured. Unlike a pill that works within an hour, this diagnostic test takes time because it relies on the movement of immune cells to the injection site. You will typically see a small red spot within 24 hours, but the final result is not ready until 48 to 72 hours after the injection. Your healthcare provider will schedule a follow-up appointment during this window to measure the size of the hardened area. If you look at the site too early or too late, the test results may be inaccurate.
Since Mycoplasma Pneumoniae extract is usually given as a single injection for diagnostic purposes, 'stopping' the medication is not usually an issue. If you are receiving it as part of a long-term allergy desensitization program, you can stop the injections, but you must consult your allergist first. Stopping immunotherapy suddenly will not cause withdrawal symptoms, but it will mean that your immune system will lose any progress it made toward becoming less sensitive to the antigen. You should never try to administer these injections yourself or change the schedule without professional medical advice.
If you miss your appointment for the initial injection, simply call your doctor's office to reschedule as soon as possible. If you have already received the injection but miss the appointment to have the results read (the 48-72 hour window), the test may be invalid. In that case, your doctor might have to wait a few weeks before repeating the test on the other arm. For those on a regular immunotherapy schedule, a missed dose usually requires a slight adjustment or reduction in the next dose to ensure your safety. Consistency is key for both diagnostic accuracy and treatment success.
No, Mycoplasma Pneumoniae extract does not cause weight gain. It is a diagnostic protein extract injected in a very tiny amount (0.1 mL) into the skin. It does not contain hormones, calories, or metabolic-altering chemicals that would lead to an increase in body fat or weight. If you notice any swelling, it is likely localized to the site of the injection and is a temporary inflammatory response, not a change in body weight. If you are experiencing unexplained weight gain, you should discuss this with your healthcare provider to find the underlying cause, as it is unrelated to this skin test.
Mycoplasma Pneumoniae can be affected by other medications, particularly those that suppress the immune system. Drugs like prednisone, chemotherapy, or biologics used for autoimmune diseases can prevent your immune system from reacting to the test, leading to a false-negative result. Additionally, certain heart medications like beta-blockers can make it dangerous to treat an allergic reaction if one occurs. It is vital to give your doctor a complete list of all your current medications, including over-the-counter vitamins and supplements. They will decide if any of your medications need to be temporarily paused before the test.
Because Mycoplasma Pneumoniae extract is a complex biological product rather than a simple chemical drug, it is not available as a 'generic' in the traditional sense. Instead, different manufacturers may produce their own versions of the extract, which are considered 'non-standardized allergenic extracts.' While they all serve the same diagnostic purpose, they are not always perfectly interchangeable. Your doctor will use a trusted brand that meets FDA manufacturing standards for purity and sterile preparation. Always ensure that the extract is being administered by a qualified professional using a product from a reputable biological laboratory.